Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Congrats to Management...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(24)
•••
Comment by mystic1689on Nov 24, 2020 4:30pm
86 Views
Post# 31963258

RE:RE:RE:RE:RE:RE:RE:RE:Congrats to Management...

RE:RE:RE:RE:RE:RE:RE:RE:Congrats to Management...

Aminvestor1234 wrote: I don't disagree with you and hope you are right. I've had this dog for years and is the 2nd worst (worst being CFX) performing stock in my portfolio of 43. Having faith in this stock is like having to trust the fortune-teller who says I'll win the 649 jackpot someday. I just have to be patient.

 


Must be a stellar portfolio of 43 to have this dog holding such a crummy rung position, it still represents a double for me.  You can just imagine how bad my bottom several rungs must be.  LOL.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities